Wang Xiaolei, Chen Ximei, Fang Jianping, Yang Changqing
Department of Gastroenternology, Institute of Digestive Disease, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, PR China.
Int J Clin Exp Pathol. 2013;6(4):586-97. Epub 2013 Mar 15.
Vascular endothelial growth factor (VEGF)-A and VEGF-C are two important molecules involving in tumor development and metastasis via angiogenesis and lymphangiogenesis. However, the combined effect of VEGF-A and VEGF-C on the growth of gastric cancer (GC) is not clear.
The correlations of VEGF-A and VEGF-C expressions with clinicopathologic parameters and prognosis were evaluated in patients with GC. Furthermore, lentivirus-mediated RNA interfering (RNAi) targeting VEGF-A and/or VEGF-C was employed to silence their expressions in SGC7901 GC cell line. Cell proliferation and apoptosis were measured in vitro. Suppressive effect lentivirus-mediated VEGF-A and/or VEGF-C silencing on GC growth was evaluated in GC bearing mice.
The patients with high expression of both VEGF-A and VEGF-C (A+C+) had larger tumor size, higher peritumoral lymphatic vessel density(P-LVD), microvessel density(MVD), lymphatic vessel invasion (LVI), lymph node(LN) metastasis, and worse prognosis than those with low expression of both VEGF-A and VEGF-C (P<0.05). Lentivirus-mediated RNAi significantly reduced the mRNA and protein expression of VEGF-A and VEGF-C in the SGC7901 cells. The Lenti-miRNA-VEGF-A+VEGF-C significantly inhibited the cell proliferation and tumor growth, compared with Lenti-miRNA-VEGF-A or Lenti-miRNA-VEGF-C (P<0.05). In addition, Lenti-miRNA- VEGF-A+VEGF-C markedly lowered the tumor size in vivo in comparison with Lenti-miRNA-VEGF-A or Lenti-miRNA-VEGF-C (P<0.05).
Expressions of both VEGF-A and VEGF-C predict worse prognosis of GC patients. Combined silencing of VEGF-A and VEGF-C markedly suppresses cancer growth than silencing of VEGF-A or VEGF-C. Thus, to inhibit the expressions of VEGF-A and VEGF-C may become a novel strategy for the treatment of GC.
血管内皮生长因子(VEGF)-A和VEGF-C是通过血管生成和淋巴管生成参与肿瘤发展和转移的两个重要分子。然而,VEGF-A和VEGF-C对胃癌(GC)生长的联合作用尚不清楚。
评估GC患者中VEGF-A和VEGF-C表达与临床病理参数及预后的相关性。此外,采用慢病毒介导的靶向VEGF-A和/或VEGF-C的RNA干扰(RNAi)来沉默SGC7901 GC细胞系中它们的表达。体外检测细胞增殖和凋亡。在荷GC小鼠中评估慢病毒介导的VEGF-A和/或VEGF-C沉默对GC生长的抑制作用。
VEGF-A和VEGF-C均高表达(A+C+)的患者比VEGF-A和VEGF-C均低表达的患者肿瘤体积更大,瘤周淋巴管密度(P-LVD)、微血管密度(MVD)、淋巴管浸润(LVI)、淋巴结(LN)转移更高,预后更差(P<0.05)。慢病毒介导的RNAi显著降低了SGC7901细胞中VEGF-A和VEGF-C的mRNA和蛋白表达。与Lenti-miRNA-VEGF-A或Lenti-miRNA-VEGF-C相比,Lenti-miRNA-VEGF-A+VEGF-C显著抑制细胞增殖和肿瘤生长(P<0.05)。此外,与Lenti-miRNA-VEGF-A或Lenti-miRNA-VEGF-C相比,Lenti-miRNA-VEGF-A+VEGF-C在体内显著降低了肿瘤大小(P<0.05)。
VEGF-A和VEGF-C的表达均预示GC患者预后较差。与单独沉默VEGF-A或VEGF-C相比,联合沉默VEGF-A和VEGF-C能更显著地抑制肿瘤生长。因此,抑制VEGF-A和VEGF-C的表达可能成为治疗GC的新策略。